Clinical trials: Hair Problems
Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety.
- Trial name
- NCT07358403
- Testing
- Dietary supplement capsule use for hair loss, Dietary supplement drinklable use for hair loss
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Alopecia, Alopecia, Androgenetic
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01904721
- Testing
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Allergan
Alopecia
Treatment of Androgenetic Alopecia in Men for 24 Weeks
A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment.
- Trial name
- MINOX (NCT04721548)
- Testing
- Minoxidil Topical Foam
- Where
- Brazil
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Hirsutism
Evaluation of Eflornithine on Facial and Forearm Skin
The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms
- Trial name
- NCT00152048
- Testing
- Eflornithine hydrochloride
- Volunteers
- 78 people
- Sponsor
- Allergan
Alopecia, Androgenetic
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
The primary objective of this study is to evaluate the safety and feasibility of the Celution and Puregraft Systems in the processing and preparation of an autologous fat graft enriched with adipose-derived regenerative cells…
- Trial name
- STYLE (NCT02503852)
- Testing
- Puregraft System, Celution System, Kerastem Therapy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Kerastem Technologies, LLC
Alopecia Areata
A Phase II Study in Patients With Alopecia Areata
This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.
- Trial name
- NCT04346316
- Testing
- SHR0302
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 94 people
- Sponsor
- Reistone Biopharma Company Limited
Menkes Disease, Occipital Horn Syndrome
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Menkes disease and occipital horn syndrome are two forms of copper deficiency that must be diagnosed and treated very early in life to prevent serious developmental problems.
- Conditions
- Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
- Trial name
- NCT00811785
- Testing
- Copper Histidine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Cyprium Therapeutics, Inc.
Alopecia Areata
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
This clinical trial attempts to investigate the efficacy of LEO 124249 ointment in the treatment of alopecia areata on the eyebrows.
- Trial name
- NCT03325296
- Testing
- LEO 124249, Ointment vehicle
- Where
- 2 sites in Denmark
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Hirsutism, Hypertrichosis
Enhanced Safety Aesthetic Laser System
The purpose of this study is to determine whether a new laser system provides better safety and efficacy than existing lasers in popular cosmetic procedures such as hair removal, treatment of cosmetically disturbing vascular…
- Conditions
- Hirsutism, Hypertrichosis, Telangiectases, Rhytides
- Trial name
- NCT00495443
- Testing
- Peterio
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Scilex Ltd.
Hypotrichosis
Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
- Trial name
- NCT01448525
- Testing
- bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Allergan
Alopecia Areata
A Study of KL130008 in Adults With Severe Alopecia Areata
The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata
- Trial name
- NCT05496426
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Alopecia Areata
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia…
- Trial name
- NCT07762443
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Alopecia
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer.
- Trial name
- NCT00801086
- Testing
- 7% (w/v) Tempol alcohol-based gel (MTS-01), alcohol-based gel
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mitos Pharmaceuticals
Androgenetic Alopecia
Minoxidil Response Testing in Males With Androgenetic Alopecia
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair.
- Trial name
- NCT02198261
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenic Alopecia, Alopecia
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia.
- Conditions
- Androgenic Alopecia, Alopecia, Baldness
- Trial name
- NCT07107841
- Testing
- Autologous Hair Follicle-Derived Secretome
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorn Biolabs Inc.
Alopecia Areata
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with…
- Trial name
- NCT06340360
- Testing
- Rezpegaldesleukin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 94 people
- Sponsor
- Nektar Therapeutics
Hair Loss, Hair Loss/Baldness
HairDx Analytical Validation Study
The HairDx Test reports genetic variants associated with the development of FPHL.
- Conditions
- Hair Loss, Hair Loss/Baldness, Female Pattern Baldness, Androgenetic Alopecia
- Trial name
- NCT04379583
- Testing
- HairDx Sample Collection Kit
- Where
- United States
- Sponsor
- Applied Biology, Inc.